Evaluating disparities in precision oncology for metastatic cancer patients
Official title: Evaluating Disparities in Precision Oncology: An Observational Trial in the Context of a Real-World Academic Practice Model
Run by Indiana University · NCT06081517 · Data updated 2026-11-12
This study looks at how different social factors affect the treatment and outcomes for people with metastatic cancer to help understand why some patients do better than others.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 10600 (estimated) |
| Sponsor | Indiana University Academic / other |
| Locations | 1 site (Indianapolis, Indiana) |
| Status | Recruiting |
| Started | January 26, 2024 |
| Main results expected | December 2028 |
| Study ends | December 2028 |
| Registry record updated | June 16, 2026 |
| Trial ID | NCT06081517 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults aged 18 and older who are planning to undergo molecular testing as part of their routine cancer care.
✕Probably not a fit
Patients who are not undergoing molecular testing or are under 18 years old may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational trial aims to collect comprehensive clinical, social, and genomic data from patients with metastatic cancer enrolled in molecular oncology tumor boards at four comprehensive cancer centers. By leveraging real-world data, the study seeks to identify factors contributing to disparities in survival and toxicity outcomes among diverse patient populations. The approach focuses on understanding how social determinants of health impact treatment efficacy and patient experiences in precision medicine.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding and mitigation of disparities in treatment outcomes for metastatic cancer patients.
How similar studies have gone: While there have been studies focusing on precision medicine, this specific approach to evaluating disparities in outcomes using real-world data is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Ability to provide written informed consent and HIPAA authorization 2. Patients must be ≥ 18 years old at the time of consent 3. Patients who have or are planning to undergo molecular testing as part of their routine cancer care Exclusion Criteria: N/A
Where it's running
-
Indiana University Health Melvin and Bren Simon Comprehensive Cancer Center
Indianapolis, Indiana, United States Recruiting
Study contacts
- Principal investigator: Bryan P Schneider, MD — Indiana University
- Study coordinator: Maria McQuade, BA
- Email: mcquadem@iu.edu
- Phone: (317) 278-5238
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Givastomig with nivolumab and chemotherapy for CLDN18.2-positive metastatic stomach or gastroesophageal junction cancer
This study will see if adding givastomig to nivolumab plus standard chemotherapy helps adults with CLDN18.2- and PD-L1-positive metastatic stomach or gastroesophageal junction cancer live longer without their disease getting worse.
-
Monthly digital financial hardship screening for people with advanced cancer
This project tests whether monthly remote digital financial hardship screening helps adults with advanced or metastatic cancer who are receiving non-curative systemic therapy.
-
Treatment of metastatic solid tumors with SLV-154
This study is testing a new treatment called SLV-154 for people with advanced solid tumors, like certain types of lung and breast cancer, to see how safe it is and how well it works.
-
Combining two immunotherapy drugs for MSI-H/dMMR advanced stomach and gastroesophageal junction cancer
This trial will try two immunotherapy drugs (balstilimab and botensilimab) as first treatment for adults with MSI‑H/dMMR, HER2‑negative advanced or metastatic stomach or gastroesophageal‑junction cancer whose tumors have PD‑L1 CPS ≥5, and will compare that to standard chemotherapy with nivolumab.
-
Testing MGC026 in patients with advanced solid tumors
This study is testing a new treatment called MGC026 to see if it can help adults with advanced solid tumors that can't be removed or have spread to other parts of the body.
-
CD70-targeted CAR-T treatment for advanced gynecologic cancer
This study is testing a new CAR-T treatment that targets CD70 to see if it can help people with advanced gynecologic cancers feel better and improve their outcomes.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.